Immunogen, Inc. logo

Immunogen, Inc. Share Price (NASDAQ: IMGN)

▲

-31.23

(-100%)

Last updated on

Bell Icon

The stock has been delisted from the stock exchange on 9 Feb 2024

Check the interactive Immunogen, Inc. Stock chart to analyse performance

Immunogen, Inc. Key Stats

Check Immunogen, Inc. key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$31.23
Open
$31.24
Market Capitalization
$8.7B
Today's Volume
$48.6M
Revenue TTM
$287.6M
EBITDA
$-78.5M
Earnings Per Share (EPS)
$-0.28
Profit Margin
-25.56%
Quarterly Earnings Growth YOY
4.08%
Return On Equity TTM
-19.88%

Global Institutional Holdings in Immunogen, Inc.

  • Name

    Holdings %

  • Vanguard Group Inc

    8.76%

  • BlackRock Inc

    7.26%

  • HHG PLC

    6.33%

  • Redmile Group, LLC

    6.27%

  • RA Capital Management, LLC

    4.77%

  • Wellington Management Company LLP

    4.75%

Analyst Recommendation on Immunogen, Inc. Stock

Rating
Trend

Buy

    85%Buy

    15%Hold

    0%Sell

Based on 20 Wall street analysts offering stock ratings for Immunogen, Inc.(by analysts ranked 0 to 5 stars)

About Immunogen, Inc.

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Organization
Immunogen, Inc.
Employees
277
CEO
Mr. Mark Joseph Enyedy
Industry
Health Technology

Important FAQs about investing in IMGN Stock from India :

What is Immunogen, Inc. share price today?

Immunogen, Inc. share price today is as on at the close of the market. Immunogen, Inc. share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Immunogen, Inc. share?

Immunogen, Inc. share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Immunogen, Inc. stock price today i.e. is closed at , lower by 100% versus the 52 week high.

How to invest in Immunogen, Inc. Stock (IMGN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Immunogen, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Immunogen, Inc. Shares .

What is the minimum amount required to buy Immunogen, Inc. Stock (IMGN) from India?

Indian investors can start investing in Immunogen, Inc. (IMGN) shares with as little as ₹87.7613 or $1 (as of September 18, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹877.61 in Immunogen, Inc. stock (as per the Rupee-Dollar exchange rate as on September 18, 2025). Learn more about fractional shares .

What are the returns that Immunogen, Inc. has given to Indian investors in the last 5 years?

Immunogen, Inc. stock has given 0.0% share price returns and 19.34% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?